Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model

Blood Cancer Journal

Volumn 2, Issue 4, 2012, Pages

  Mori, F ^a   Ishida, T ^a   Ito, A ^a   Sato, F ^a   Masaki, A ^a   Takino, H ^a   Ri, M ^a   Kusumoto, S ^a   Komatsu, H ^a   Ueda, R ^a   Inagaki, H ^a   Iida, S ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Bevacizumab; IL 2R null (NOG) mouse; Lymphoma; NOD Shi scid; Tumor microenvironment

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; PREDNISOLONE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; MONOTHERAPY; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR ENGRAFTMENT; TUMOR MICROENVIRONMENT; TUMOR NECROSIS; TUMOR VASCULARIZATION;

EID: 84864026702     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.12     Document Type: Article

References (40)

1. Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011; 30: 13-25.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
3. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
5. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K et al. NOD/SCID/ gcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100: 3175-3182.
6. Ito M, Kobayashi K, Nakahata T. NOD/Shi-scid IL2rgnull (NOG) micemore appropriate for humanized mouse models. Curr Top Microbiol Immunol 2008; 324: 53-76.
7. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
10. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
11. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Marcello J, Reardon DA, Quinn JA et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
12. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
13. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
14. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
15. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the firstline treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
16. Nogai H, Dörken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011; 29: 1803-1811.
17. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
18. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
19. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics Int 2004; 11: 36-42.
20. Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 2004; 10: 7529-7539.
21. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6: 4950-4956.
22. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today 1993; 14: 264-270.
23. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 2009; 58: 1195-1206.
24. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol 2009; 183: 4782-4791.
25. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004; 104: 2893-2902.
26. Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996; 56: 4032-4039.
27. Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009; 20: 413-424.
28. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008; 49: 522-527.
29. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591.
30. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
31. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671-680.
32. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-427.
33. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J et al. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998-1005.
34. Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RJ, Hammer AS et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol 2007; 170: 1362-1369.
35. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009; 50: 728-735.
36. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
37. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
38. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
39. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
40. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261.